SarcopeniaNCT07522359
A Short-Bout Combined Aerobic and Resistance Exercise Program in Older Adults With Diabetes and Probable Sarcopenia
A study testing Short-Bout Combined Exercise Program in people with Sarcopenia and Diabetes, run by Sun Yat-sen University.
Trial summary
Older adults with diabetes are at high risk of developing sarcopenia. A preclinical stage, known as "probable sarcopenia" (defined by low muscle strength), represents a critical window for early intervention. Physical activity is an effective strategy, but many patients struggle to maintain regular exercise. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Sarcopenia, Diabetes
- What is being tested?
- Short-Bout Combined Exercise Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 73 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2026to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥60 years, diagnosed with type 2 diabetes mellitus (T2DM) for ≥1 year.
- Meet the Asian Working Group for Sarcopenia (AWGS) 2025 criteria for probable sarcopenia.
- Physical activity <150 minutes per week of moderate-intensity aerobic activity.
- Conscious, able to communicate effectively in written or spoken language.
- Able to use a smartphone independently (or with minimal assistance).
- Voluntarily participate and provide written informed consent.
Who cannot join
- Confirmed sarcopenia based on AWGS 2025.
- History or current diagnosis of psychiatric disorders, or severe cognitive impairment.
- Severe acute or chronic diabetic complications (e.g., diabetic ketoacidosis, proliferative diabetic retinopathy, stage IV-V diabetic nephropathy).
- Severe congestive heart failure (NYHA class III-IV), or acute cardiac event, syncope, or loss of consciousness within the past year.
- Severe pulmonary, hepatic, or renal insufficiency, or active malignancy.
- Concurrent participation in another exercise intervention study.
Show all 10Show fewer
- Severe joint or muscle disease that strictly limits exercise (e.g., severe osteoarthritis, fracture, or other significant functional impairment), or other absolute contraindications to exercise.
- Unintentional weight change >5% or major changes in medication regimen within the 3 months prior to enrollment.
- Classified as poor health status (Group 3) according to the Chinese Guideline for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2024 Edition).
- Implanted electronic medical device (e.g., cardiac pacemaker).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Effect of a Short-Bout Combined Aerobic and Resistance Exercise Program on Physical Activity and Muscle Strength in Older Adults With Diabetes and Probable Sarcopenia: A Randomized Controlled Trial
Older adults with diabetes are at high risk of developing sarcopenia. A preclinical stage, known as "probable sarcopenia" (defined by low muscle strength), represents a critical window for early intervention. Physical activity is an effective strategy, but many patients struggle to maintain regular exercise. This parallel-group randomized controlled trial aims to evaluate the effectiveness of a 12-week home-based, short-bout combined aerobic and resistance exercise program on physical activity level and muscle strength among older adults with diabetes and probable sarcopenia.
Read the detailed description
The control group will receive usual community-based diabetes care. In addition to usual care, the intervention group will receive an individualized exercise program delivered in a short-bout, high-frequency format (resistance training: 3 days per week, three bouts per day at moderate intensity; aerobic training: 5 days per week, three bouts per day at moderate intensity). Primary outcomes are physical activity level and muscle strength. Assessments will be conducted at baseline, 12 weeks (post-intervention), and 24 weeks (follow-up).
- Conditions
- Sarcopenia, Diabetes
- Being tested
- Short-Bout Combined Exercise Program
- Medical subject headings
- Sarcopenia, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Short-Bout Combined Exercise ProgramBehavioural
A 12-week home-based short-bout combined aerobic and resistance exercise program.
| Study group | Role | What they receive |
|---|---|---|
| Short-Bout Combined Aerobic and Resistance Exercise | Experimental | Participants in the intervention arm will receive a 12-week home-based, short-bout combined aerobic and resistance exercise program in addition to usual community-based diabetes care. The program is designed according to the definition of short-bout accumulated exercise (SBAE), in which exercise is accumulated in multiple bouts of ≤10 minutes each, performed several times per day. Resistance training is performed 3 days per week with 3 bouts per day. Each bout consists of 2 exercises, with each exercise performed as 2 sets of 10 repetitions at moderate intensity. Aerobic training is performed 5 days per week with 3 bouts of 10 minutes each per day at moderate intensity. Receives: Behavioral: Short-Bout Combined Exercise Program |
| Usual Community Diabetes Care | No intervention | Participants receive usual diabetes care as provided in community settings, including routine medical follow-up, standard health education, and diabetes management support from community health centers. No structured exercise program or additional intervention is provided. After the trial, control participants are sent the same exercise program materials as the intervention group, and they can voluntarily choose to access and view them. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Physical Activity Level
Physical activity level measured using the Physical Activity Scale for the Elderly (PASE). The PASE score ranges from 0 to 400 or more, with higher scores indicating higher levels of physical activity.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Muscle Strength
Grip strength (kg) measured using a hand grip dynamometer. Higher values indicate greater muscle strength.
Measured: Baseline, 12 weeks, and 24 weeks
Secondary outcomes (30)
Change in Appendicular Skeletal Muscle Mass Index
Appendicular skeletal muscle mass index (kg/m²), calculated as appendicular skeletal muscle mass divided by height squared, assessed using bioelectrical impedance analysis (BIA). Higher values indicate greater relative muscle mass.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Skeletal Muscle Mass
Skeletal muscle mass (kg) assessed by bioelectrical impedance analysis (BIA) using a multi-frequency body composition analyzer. Measurements are performed with participants standing barefoot on the device electrodes. Higher values indicate greater muscle mass.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Physical Performance
Physical Performance measured by the 6-meter walking test. Participants are instructed to walk at their usual pace along a 6-meter course. The time to complete the course is recorded, and gait speed (m/s) is calculated.
Measured: Baseline, 12 weeks, and 24 weeks
Reversal rate of probable sarcopenia
Proportion of participants in the intervention group who reverse from probable sarcopenia to normal status, compared to the control group. Probable sarcopenia is defined according to AWGS 2025 criteria (low handgrip strength).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Glycated Hemoglobin
Glycated hemoglobin (HbA1c) assessed via venous blood sample. Reported as percentage (%), with higher values indicating poorer glycemic control.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Fasting Plasma Glucose
Fasting plasma glucose measured via venous blood sample after at least an 8-hour overnight fast. Reported in millimoles per liter (mmol/L). Higher values indicate poorer glycemic control (a worse outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Sarcopenia Awareness
Sarcopenia awareness measured by the Consequences dimension of the Sarcopenia Awareness Questionnaire (SAQ). One point is awarded for each correct answer identified, with no penalty for incorrect selections. Scores range from 0 to 3, with higher scores indicating greater awareness of sarcopenia consequences (a better outcome). A score of less than 3 indicates insufficient sarcopenia risk awareness.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Sarcopenia risk
Sarcopenia risk assessed by the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire. The SARC-F comprises 5 items, each scored from 0 to 2. Scores range from 0 to 10, with higher scores indicating greater likelihood of sarcopenia (a worse outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Nutritional Status
Nutritional status assessed by the Mini-Nutritional Assessment Short Form (MNA-SF). Scores range from 0 to 14, with higher scores indicating better nutritional status.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Frailty Level
Frailty assessed by the Clinical Frailty Scale (CFS), which ranges from 1 (very fit) to 9 (terminally ill). Higher scores indicate greater frailty (worse outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Fall risk
Fall risk assessed using the Stopping Elderly Accidents, Deaths, and Injuries (STEADI) fall risk self-assessment tool. The STEADI comprises 12 items answered with yes or no. The first 2 items are scored 2 points for a "yes" response and the remaining 10 items are scored 1 point for a "yes" response, with all "no" responses scored 0. Total scores range from 0 to 14, with higher scores indicating greater fall risk (a worse outcome).
Measured: Baseline, at 12 weeks post-intervention, and at 24 weeks post-intervention
Change in Depressive Symptoms
Depressive symptoms assessed by the Patient Health Questionnaire-2 (PHQ-2). The PHQ-2 comprises 2 items, each scored from 0 to 3. Scores range from 0 to 6, with higher scores indicating greater severity of depressive symptoms (a worse outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Number of Adverse Events
Number of adverse events occurring during the study period, including falls, unplanned hospital admissions, severe hypoglycemic events, and fracture events.
Measured: Throughout the study (Baseline to 24 weeks)
Cost-Utility Analysis Indicators
Cost-utility analysis (CUA) using quality-adjusted life years (QALYs) as the utility outcome.
Measured: Baseline, 24 weeks
Process Evaluation Indicators
Process Evaluation Indicators include Fidelity, Dose, Reach (Recruitment Rate, Retention Rate), Adaptations, Adherence, Exploratory Mechanism Analysis (Participant Responses, Mediators, Unexpected Pathways), Context Factors, and Qualitative Interviews.
Measured: Throughout the study (Baseline to 24 weeks)
Change in Total Body Water
Total body water assessed by bioelectrical impedance analysis (BIA) using a multi-frequency body composition analyzer. Measurements are performed with participants standing barefoot on the device electrodes. Reported in liters (L).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Inorganic Salt Mass
Inorganic salt mass assessed by bioelectrical impedance analysis (BIA) using a multi-frequency body composition analyzer. Measurements are performed with participants standing barefoot on the device electrodes. Reported in kilograms (kg). Higher values indicate greater mineral content.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Fat Mass
Fat mass assessed by bioelectrical impedance analysis (BIA) using a multi-frequency body composition analyzer. Measurements are performed with participants standing barefoot on the device electrodes. Reported in kilograms (kg). Higher values indicate greater body fat mass (a worse outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Yubi-wakka Test
Sarcopenia screening assessed using the Yubi-wakka (finger-ring) test. Participants form a ring with the thumbs and index fingers of both hands and encircle the thickest part of their non-dominant calf. Results are classified into three categories: "bigger" (calf circumference larger than finger-ring, lowest risk), "just fits" (calf circumference equal to finger-ring, intermediate risk), or "smaller" (calf circumference smaller than finger-ring, highest risk). A "smaller" result indicates the greatest risk of sarcopenia (a worse outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Body Fat Percentage
Body fat percentage assessed by bioelectrical impedance analysis (BIA) using a multi-frequency body composition analyzer. Measurements are performed with participants standing barefoot on the device electrodes. Reported as a percentage (%). Higher values indicate greater body fat accumulation.
Measured: Baseline, 12 weeks, and 24 weeks
Change in Protein Mass
Protein mass assessed by bioelectrical impedance analysis (BIA) using a multi-frequency body composition analyzer. Measurements are performed with participants standing barefoot on the device electrodes. Reported in kilograms (kg). Higher values indicate greater body protein mass.
Measured: Baseline, 12 weeks, and 24 weeks
Change in EuroQol-5D-5L Scores
EuroQol-5D-5L (EQ-5D-5L) includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each rated from 1 to 5, and a visual analogue scale (VAS) from 0 (worst health) to 100 (best health).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Affective Attitude toward Physical Activity
Affective attitude toward physical activity assessed using the Affective Attitude subscale of the Multi-Process Action Control (M-PAC) framework questionnaire. The subscale comprises 3 items rated on a 7-point Likert scale. Scores range from 3 to 21, with higher scores indicating more positive affective attitudes toward physical activity (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Instrumental Attitude toward Physical Activity
Instrumental attitude toward physical activity assessed using the Instrumental Attitude subscale of the Multi-Process Action Control (M-PAC) framework questionnaire. The subscale comprises 3 items rated on a 7-point Likert scale. Scores range from 3 to 21, with higher scores indicating more positive instrumental attitudes toward physical activity (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Perceived Capability for Physical Activity
Perceived capability to engage in regular physical activity assessed using the Perceived Capability subscale of the Multi-Process Action Control (M-PAC) framework questionnaire. The subscale comprises 3 items rated on a 5-point Likert scale. Scores range from 3 to 15, with higher scores indicating greater perceived capability for physical activity (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Perceived Opportunity for Physical Activity
Perceived opportunity for physical activity assessed using the Perceived Capability subscale of the Multi-Process Action Control (M-PAC) framework questionnaire. The subscale comprises 3 items rated on a 5-point Likert scale. Scores range from 3 to 15, with higher scores indicating greater perceived opportunity for physical activity (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Intention to Engage in Physical Activity
Intention to engage in physical activity assessed using a single-item measure of the Multi-Process Action Control (M-PAC) framework questionnaire. Participants report the number of sessions per week they intend to engage in physical activity. As an open-ended item, there is no fixed maximum score, with higher values indicating greater intention to engage in physical activity (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Physical Activity Regulation Behaviours
Physical activity regulation behaviours assessed using a 6-item scale, which forms part of the Multi-Process Action Control (M-PAC) framework questionnaire. Participants rate their agreement with six statements about self-regulatory behaviours on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). Scores range from 6 to 30, with higher scores indicating greater use of self-regulatory strategies to maintain physical activity (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Physical Activity Habit
Physical activity habit assessed using the Self-Report Behavioural Automaticity Index (SRBAI), a 4-item subscale of the Self-Report Habit Index. Participants rate their agreement with four statements about the automaticity of physical activity behaviours on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). Scores range from 4 to 20, with higher scores indicating greater automaticity of physical activity behaviour (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Change in Physical Activity Identity
Physical activity identity assessed using the Exercise Identity Scale (EIS). Participants rate their agreement with four statements regarding physical activity identity on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). Scores range from 4 to 20, with higher scores indicating stronger identification with being a physically active person (a better outcome).
Measured: Baseline, 12 weeks, and 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start1 Apr 2026 (estimated)
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 73 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lu Han, Sun Yat-sen University
- Investigators
- Lu Han, PhD Stud., Principal investigator, Sun Yat-sen University, School of Nursing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07522359
- Sponsor's protocol ID
- L2024SYSU-HL-057
- Other IDs
- 2025A1515011403
- Status last verified
- Apr 2026
- First submitted
- 27 Mar 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of a Short-Bout Combined Aerobic and Resistance Exercise Program on Physical Activity and Muscle Strength in Older Adults With Diabetes and Probable Sarcopenia: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07522359
- Acronym / sponsor ID
- L2024SYSU-HL-057
- Conditions
- Sarcopenia, Diabetes
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 73 participants (estimated)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Older adults with diabetes are at high risk of developing sarcopenia. A preclinical stage, known as "probable sarcopenia" (defined by low muscle strength), represents a critical window for early intervention. Physical activity is an effective strategy, but many patients struggle to maintain regular exercise. This parallel-group randomized controlled trial aims to evaluate the effectiveness of a 12-week home-based, short-bout combined aerobic and resistance exercise program on physical activity level and muscle strength among older adults with diabetes and probable sarcopenia.
Detailed description
The control group will receive usual community-based diabetes care. In addition to usual care, the intervention group will receive an individualized exercise program delivered in a short-bout, high-frequency format (resistance training: 3 days per week, three bouts per day at moderate intensity; aerobic training: 5 days per week, three bouts per day at moderate intensity). Primary outcomes are physical activity level and muscle strength. Assessments will be conducted at baseline, 12 weeks (post-intervention), and 24 weeks (follow-up).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Short-Bout Combined Aerobic and Resistance Exercise | Experimental | Behavioral: Short-Bout Combined Exercise ProgramParticipants in the intervention arm will receive a 12-week home-based, short-bout combined aerobic and resistance exercise program in addition to usual community-based diabetes care. The program is designed according to the definition of short-bout accumulated exercise (SBAE), in which exercise is accumulated in multiple bouts of ≤10 minutes each, performed several times per day. Resistance training is performed 3 days per week with 3 bouts per day. Each bout consists of 2 exercises, with each exercise performed as 2 sets of 10 repetitions at moderate intensity. Aerobic training is performed 5 days per week with 3 bouts of 10 minutes each per day at moderate intensity. |
| Usual Community Diabetes Care | No intervention | –Participants receive usual diabetes care as provided in community settings, including routine medical follow-up, standard health education, and diabetes management support from community health centers. No structured exercise program or additional intervention is provided. After the trial, control participants are sent the same exercise program materials as the intervention group, and they can voluntarily choose to access and view them. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥60 years, diagnosed with type 2 diabetes mellitus (T2DM) for ≥1 year.
- Meet the Asian Working Group for Sarcopenia (AWGS) 2025 criteria for probable sarcopenia.
- Physical activity <150 minutes per week of moderate-intensity aerobic activity.
- Conscious, able to communicate effectively in written or spoken language.
- Able to use a smartphone independently (or with minimal assistance).
Key exclusion criteria (10 listed)
- Confirmed sarcopenia based on AWGS 2025.
- History or current diagnosis of psychiatric disorders, or severe cognitive impairment.
- Severe acute or chronic diabetic complications (e.g., diabetic ketoacidosis, proliferative diabetic retinopathy, stage IV-V diabetic nephropathy).
- Severe congestive heart failure (NYHA class III-IV), or acute cardiac event, syncope, or loss of consciousness within the past year.
- Severe pulmonary, hepatic, or renal insufficiency, or active malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Short-Bout Combined Exercise ProgramA 12-week home-based short-bout combined aerobic and resistance exercise program. | Behavioural | Short-Bout Combined Aerobic and Resistance Exercise |
Primary outcome
Change in Physical Activity Level
Time frame: Baseline, 12 weeks, and 24 weeks
Physical activity level measured using the Physical Activity Scale for the Elderly (PASE). The PASE score ranges from 0 to 400 or more, with higher scores indicating higher levels of physical activity.
Change in Muscle Strength
Time frame: Baseline, 12 weeks, and 24 weeks
Grip strength (kg) measured using a hand grip dynamometer. Higher values indicate greater muscle strength.
30 secondary outcomes
Change in Appendicular Skeletal Muscle Mass Index
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Skeletal Muscle Mass
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Physical Performance
Time frame: Baseline, 12 weeks, and 24 weeks
Reversal rate of probable sarcopenia
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Glycated Hemoglobin
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Fasting Plasma Glucose
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Sarcopenia Awareness
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Sarcopenia risk
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Nutritional Status
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Frailty Level
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Fall risk
Time frame: Baseline, at 12 weeks post-intervention, and at 24 weeks post-intervention
Change in Depressive Symptoms
Time frame: Baseline, 12 weeks, and 24 weeks
Number of Adverse Events
Time frame: Throughout the study (Baseline to 24 weeks)
Cost-Utility Analysis Indicators
Time frame: Baseline, 24 weeks
Process Evaluation Indicators
Time frame: Throughout the study (Baseline to 24 weeks)
Change in Total Body Water
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Inorganic Salt Mass
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Fat Mass
Time frame: Baseline, 12 weeks, and 24 weeks
Yubi-wakka Test
Time frame: Baseline, 12 weeks, and 24 weeks
Body Fat Percentage
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Protein Mass
Time frame: Baseline, 12 weeks, and 24 weeks
Change in EuroQol-5D-5L Scores
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Affective Attitude toward Physical Activity
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Instrumental Attitude toward Physical Activity
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Perceived Capability for Physical Activity
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Perceived Opportunity for Physical Activity
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Intention to Engage in Physical Activity
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Physical Activity Regulation Behaviours
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Physical Activity Habit
Time frame: Baseline, 12 weeks, and 24 weeks
Change in Physical Activity Identity
Time frame: Baseline, 12 weeks, and 24 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Sarcopenia
Enrolling by invitation
Exercise Intervention for Breast Cancer Patients With Sarcopenia
Sarcopenia, Breast Cancer
Active, not recruiting
Group Exercise Program Supported By Audiovisual Media During Hemodialysis
Chronic Kidney Failure, Hemodialysis
Active, not recruitingObservational study
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia, Sarcopenia
RecruitingObservational study
Sarcopenia and Training Outcomes in Post-cardiac Surgery Patients
Sarcopenia, Cardiac Surgery
Not yet recruitingObservational study
CT Based Assessment of Sarcopenia and Its Association With Biologic Treatment Outcomes in Inflammatory Bowel Disease Patients
CT-Assessed Sarcopenia Outcomes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lu Han, PhD Stud. principal investigator
Sun Yat-sen University, School of Nursing
Questions about this trial
What is this clinical trial studying?
A study testing Short-Bout Combined Exercise Program in people with Sarcopenia and Diabetes, run by Sun Yat-sen University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lu Han, PhD Stud. (+8617539344466, hanlu9@mail2.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Physical Activity Level (time frame: Baseline, 12 weeks, and 24 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.